Physician profile
Sejal Dave
NPI 1124234901
$4,018.57
in general payments reported to CMS, 2019-2025
50 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $134 · 2021: $236 · 2024: $1,158 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749 · Consulting Fee: $525 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.45 |
| Consulting Fee | $525.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $602.53 | 2019-2025 | Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $337.99 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $308.59 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $271.43 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $155.72 | 2019-2025 | Vyloy |
| Daiichi Sankyo INC. | $147.57 | 2019-2025 | Enhertu |
| Eisai INC. | $143.29 | 2021-2024 | |
| Janssen Biotech, INC. | $132.52 | 2019-2025 | Erleada, Carvykti |
| Stemline Therapeutics INC. | $125.01 | 2024 | Orserdu |
| Pharmacosmos Therapeutics INC. | $121.09 | 2025 | Monoferric |
| Genentech USA, INC. | $119.06 | 2021-2025 | Polivy |
| Adc Therapeutics America, INC. | $118.52 | 2024 | |
| Caris Mpi, INC. | $101.95 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $79.02 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.33 | 2019-2025 | Gilotrif |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sejal Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.